Free Trial

Krystal Biotech (KRYS) Stock Price, News & Analysis

Krystal Biotech logo
$143.01 +1.66 (+1.17%)
Closing price 07/3/2025 03:17 PM Eastern
Extended Trading
$146.50 +3.49 (+2.44%)
As of 07/3/2025 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Krystal Biotech Stock (NASDAQ:KRYS)

Key Stats

Today's Range
$140.70
$143.09
50-Day Range
$123.36
$170.57
52-Week Range
$122.80
$219.34
Volume
168,281 shs
Average Volume
287,155 shs
Market Capitalization
$4.13 billion
P/E Ratio
34.38
Dividend Yield
N/A
Price Target
$211.13
Consensus Rating
Buy

Company Overview

Krystal Biotech Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
91st Percentile Overall Score

KRYS MarketRank™: 

Krystal Biotech scored higher than 91% of companies evaluated by MarketBeat, and ranked 286th out of 2,814 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Krystal Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Krystal Biotech has only been the subject of 4 research reports in the past 90 days.

  • Read more about Krystal Biotech's stock forecast and price target.
  • Earnings Growth

    Earnings for Krystal Biotech are expected to grow by 64.17% in the coming year, from $6.14 to $10.08 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Krystal Biotech is 34.38, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.53.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Krystal Biotech is 34.38, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 27.40.

  • Price to Book Value per Share Ratio

    Krystal Biotech has a P/B Ratio of 4.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Krystal Biotech's valuation and earnings.
  • Percentage of Shares Shorted

    12.15% of the float of Krystal Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Krystal Biotech has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in Krystal Biotech has recently increased by 3.77%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Krystal Biotech does not currently pay a dividend.

  • Dividend Growth

    Krystal Biotech does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    12.15% of the float of Krystal Biotech has been sold short.
  • Short Interest Ratio / Days to Cover

    Krystal Biotech has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in Krystal Biotech has recently increased by 3.77%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Krystal Biotech has a news sentiment score of 0.17. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 19 news articles for Krystal Biotech this week, compared to 7 articles on an average week.
  • Search Interest

    6 people have searched for KRYS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    Only 2 people have added Krystal Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Krystal Biotech insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.70% of the stock of Krystal Biotech is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    86.29% of the stock of Krystal Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Krystal Biotech's insider trading history.
Receive KRYS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Krystal Biotech and its competitors with MarketBeat's FREE daily newsletter.

KRYS Stock News Headlines

Analysts Offer Predictions for Krystal Biotech Q2 Earnings
Why Elon is funding the “Quantum Power Grid”
Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly becoming one of the most profitable stories of the year.
FY2026 EPS Estimates for Krystal Biotech Reduced by Analyst
Peering Into Krystal Biotech's Recent Short Interest
See More Headlines

KRYS Stock Analysis - Frequently Asked Questions

Krystal Biotech's stock was trading at $156.66 at the beginning of 2025. Since then, KRYS stock has decreased by 8.7% and is now trading at $143.01.

Krystal Biotech, Inc. (NASDAQ:KRYS) released its quarterly earnings results on Tuesday, May, 6th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.38 by $0.18. The business had revenue of $88.18 million for the quarter, compared to analyst estimates of $98.66 million. Krystal Biotech had a trailing twelve-month return on equity of 14.64% and a net margin of 37.17%.
Read the conference call transcript
.

Krystal Biotech (KRYS) raised $30 million in an initial public offering (IPO) on Wednesday, September 20th 2017. The company issued 3,000,000 shares at a price of $9.00-$11.00 per share. Ladenburg Thalmann acted as the underwriter for the IPO.

Shares of KRYS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Krystal Biotech investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
5/06/2025
Today
7/03/2025
Next Earnings (Estimated)
8/04/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KRYS
Fax
N/A
Employees
210
Year Founded
2017

Price Target and Rating

Average Stock Price Target
$211.13
High Stock Price Target
$245.00
Low Stock Price Target
$155.00
Potential Upside/Downside
+47.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
34.38
Forward P/E Ratio
23.29
P/E Growth
N/A
Net Income
$89.16 million
Pretax Margin
41.39%

Debt

Sales & Book Value

Annual Sales
$290.52 million
Cash Flow
$4.77 per share
Price / Cash Flow
29.98
Book Value
$32.90 per share
Price / Book
4.35

Miscellaneous

Free Float
24,940,000
Market Cap
$4.13 billion
Optionable
Optionable
Beta
0.67

Social Links

A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:KRYS) was last updated on 7/4/2025 by MarketBeat.com Staff
From Our Partners